Hong Kong Infrastructure Stock News

China Mengniu Dairy (SEHK:2319) has issued preliminary 2025 guidance flagging a 7% to 8% revenue decline and a slightly lower operating margin, while also being removed from the Hang Seng China Enterprises Index. See our latest analysis for China Mengniu Dairy. The latest guidance and index removal come after a mixed share price pattern, with a 12.1% year to date share price return and a 12.5% 90 day share price return, but a 13.0% negative total shareholder return over the past year. This...

Shanghai Henlius Biotech (SEHK:2696) has drawn fresh attention after China’s National Medical Products Administration approved phase 1 trials for two solid tumour candidates, HLX316 and HLX3901, both backed by positive preclinical safety and efficacy data. See our latest analysis for Shanghai Henlius Biotech. The recent NMPA green light for HLX316 and HLX3901 comes as Shanghai Henlius Biotech’s share price sits at HK$67.95, with a 90 day share price return of 13.53% and a very large 3 year...

Genscript Biotech has reported its full-year 2025 results, with sales rising to US$959.53 million while the company moved from a prior-year net income of US$2.96 billion to a net loss of US$532.83 million, alongside higher basic and diluted losses per share. A key driver of this sharp swing in reported profitability is the absence of the previous year’s very large one-time unrealised gain from deconsolidation, which means the latest figures chiefly reflect the underlying operating profile...

Dongfeng Motor Group (SEHK:489) has just been dropped from the FTSE All-World Index (USD). This index change can affect how some global funds treat the stock in their portfolios. See our latest analysis for Dongfeng Motor Group. Recent moves in Dongfeng Motor Group’s share price have been mixed, with an 8.4% 90 day share price return alongside a very large 3 year total shareholder return of about 3x. This suggests longer term momentum remains strong even as the latest index change and...

Zhejiang Leapmotor's recent pre-earnings update, ahead of its 16 March 2026 results, has drawn investor attention to margin trends, electric vehicle deliveries, and free cash flow strength as key indicators of its current operating health. This heightened focus on revenue per unit, gross margin quality, and management guidance on volumes and pricing puts Leapmotor’s underlying unit economics and cash generation firmly in the spotlight. We’ll now examine how this intensified focus on...

On 9 March 2026, Kelun-Biotech and Harbour BioMed announced that China’s NMPA approved the IND application for SKB575/HBM7575, a long-acting bispecific antibody for atopic dermatitis with a dual TSLP-based mechanism and extended half-life enabling subcutaneous dosing. This IND approval highlights Kelun-Biotech’s growing capabilities in innovative biologics and positions SKB575/HBM7575 as a potentially differentiated long-interval therapy candidate in atopic dermatitis. We will now examine...

Context for Shanghai Junshi Biosciences after recent share performance Shanghai Junshi Biosciences (SEHK:1877) has seen mixed share performance recently, with a small gain over the past week but declines over the past month and past 3 months, drawing attention to how its fundamentals line up. For investors tracking the stock longer term, the shares show a negative total return over 3 and 5 years, while the 1 year total return is positive. This can make current pricing and expectations...

Oshidori International Holdings (SEHK:622) issued new earnings guidance pointing to a net profit of HK$171.4 million for 2025, compared with a HK$194.7 million loss in 2024. This highlights a sharp swing in reported performance. See our latest analysis for Oshidori International Holdings. The guidance appears to sit against very strong recent momentum, with a 30 day share price return of 45.45% and a 90 day gain of 120%, while the 1 year total shareholder return of 266.67% points to sustained...

What recent performance says about Alphamab Oncology Alphamab Oncology (SEHK:9966) has seen mixed share price performance recently, with a 0.6% move over the past day and around 9.6% over the past week, but negative returns over the month and the past 3 months. See our latest analysis for Alphamab Oncology. With the share price at HK$8.6, Alphamab Oncology’s recent 7 day share price return of 9.6% sits against a 30 day decline of 3.4% and a 90 day decline of 19.8%. The 1 year total...

China Chengtong Development Group (SEHK:217) has just posted its FY 2025 first half results, with revenue of HK$205.4 million, basic EPS of HK$0.001659 and net income of HK$9.9 million setting the tone for this reporting season. The company has seen revenue move from HK$323.5 million in 1H 2024 to HK$229.2 million in 2H 2024 and now HK$205.4 million in 1H 2025, while EPS shifted from HK$0.004484 to HK$0.002005 and then HK$0.001659 over the same periods. This gives investors a clear view of...

Investor focus around China Telecom (SEHK:728) has intensified ahead of the 24 March 2026 board meeting, where directors are set to approve 2025 annual results and review a proposed final dividend. See our latest analysis for China Telecom. At a share price of HK$5.09, China Telecom’s 30 day share price return of 3.88% contrasts with a 90 day share price decline of 9.91%. Its 5 year total shareholder return of 166.19% points to a much stronger long term outcome than its 1 year total...

Recent performance snapshot and business profile Robosense Technology (SEHK:2498) has seen mixed share performance recently, with a 1 day return of about a 3% decline and a past 3 months return near an 8% decline, putting its LiDAR focused business under closer investor review. The company reports HK$1,704.246 in revenue and a net loss of HK$382.504, while annual revenue growth is 27.552% and net income growth is very large, reflecting a shift in its loss profile. See our latest analysis for...

Why China Risun Group is back on traders’ radar China Risun Group (SEHK:1907) drew fresh attention after its share price moved sharply higher on 12 March, with trading volumes picking up ahead of the earnings release scheduled for 20 March 2026. See our latest analysis for China Risun Group. That one day move sits on top of a 40.08% 7 day share price return and a 60.71% 90 day share price return, with the latest HK$3.6 level reflecting building short term momentum, even though the 5 year...

Dividend increase and full year results put income focus on CITIC Telecom CITIC Telecom International Holdings (SEHK:1883) has drawn fresh attention after releasing its 2025 results, pairing steady earnings with a slightly higher dividend that may interest income focused investors. See our latest analysis for CITIC Telecom International Holdings. The latest full year earnings and dividend announcement have come alongside a 1 month share price return of 4.23% and an 8.84% year to date share...

Playmates Holdings (SEHK:635) has kicked off FY 2025 with first half revenue of HK$261.1 million and a loss per share of HK$0.10, keeping the focus firmly on the earnings line. Over the last few reporting halves, the toy maker has seen revenue move from HK$526.7 million in 1H 2024 to HK$565.6 million in 2H 2024 and then to HK$261.1 million in 1H 2025. At the same time, losses excluding extra items shifted from HK$159.9 million to HK$222.4 million and then to HK$205.6 million. Investors are...

TOM Group FY 2025 earnings: losses continue but margin picture is shifting TOM Group (SEHK:2383) has reported its FY 2025 first half results with revenue of HK$338.7 million and a basic EPS loss of HK$0.024, while net income excluding extra items came in at a loss of HK$95.0 million, keeping the group in the red. The company has seen revenue move from HK$334.9 million in 1H 2024 to HK$404.7 million in 2H 2024 and HK$338.7 million in 1H 2025, alongside a series of half year EPS losses from...

CITIC Resources Holdings (SEHK:1205) just posted its FY 2025 first half numbers, with revenue of HK$9.4b and basic EPS of HK$0.019, alongside net income of HK$151.7m, giving investors fresh data on how the business is tracking. The company has seen revenue move from HK$3.9b in 1H 2024 to HK$5.6b in 2H 2024 and now HK$9.4b in 1H 2025, while basic EPS shifted from HK$0.045 to HK$0.028 and then HK$0.019 over the same periods. This pattern puts the spotlight firmly on how sustainably the group...

WuXi Biologics (Cayman) (SEHK:2269) received six company awards and two individual awards at the 2026 Asia Pacific Biopharma Excellence Awards. The company entered a collaboration with Earendil Labs to co develop multiple novel antibody and antibody drug conjugate therapeutics. For investors tracking contract research, development and manufacturing organizations, WuXi Biologics sits at the center of global demand for outsourced biologics work. The new Asia Pacific awards span development,...

Guidance points to profit to loss swing Star Plus Legend Holdings (SEHK:6683) has guided for a consolidated loss of up to CN¥52.0 million for 2025, compared with a consolidated profit of CN¥50.2 million for 2024. The board links this shift mainly to slower IP content launches affecting its IP creation segment, lower gross margins in the expanding new retail business, and a non cash impairment provision on certain trade receivables tied to recent geopolitical developments. See our latest...

Xinyi Solar Holdings Limited recently reported full-year 2025 results showing sales of CNY 20,861.16 million and net income of CNY 844.53 million, while also declaring a final ordinary cash dividend of HK$0.008 per share, subject to shareholder approval on 29 May 2026 and payable on 03 July 2026. The year-on-year declines in both revenue and earnings per share place renewed attention on how Xinyi Solar balances capital returns with profit pressures. We will now examine how the weaker...

MTR (SEHK:66) has just posted its FY 2025 first half scorecard, with revenue of HK$27.4b, net income of HK$7.7b and EPS of HK$1.24, while its trailing twelve month revenue sits at HK$55.5b, net income at HK$15.3b and EPS at HK$2.36. The company has seen revenue move from HK$29.3b and EPS of HK$0.97 in 1H 2024 to HK$30.7b and EPS of HK$1.57 in 2H 2024, before landing at the latest half year levels, giving you a clear arc of how the top and bottom line have tracked into this result. With net...

SF Real Estate Investment Trust (SEHK:2191) has posted its FY 2025 numbers with first half revenue of HK$224.6 million and basic EPS of HK$0.44 loss, while the trailing 12 month figures show revenue of HK$445.4 million and basic EPS of HK$0.41 loss. Over the past three reported half year periods, revenue has moved from HK$221.8 million in 1H FY 2024 to HK$224.1 million in 2H FY 2024 and HK$224.6 million in 1H FY 2025, with basic EPS shifting from HK$0.02 to HK$0.38 loss and then HK$0.44 loss...

CITIC Telecom International Holdings (SEHK:1883) has posted its FY 2025 results with second half revenue of HK$4.8b and basic EPS of HK$0.12, while trailing twelve month figures show HK$9.6b in revenue and basic EPS of HK$0.25, alongside earnings growth of 1.1% and a net profit margin of 9.6%. The company has seen revenue move from HK$4.7b and basic EPS of HK$0.12 in 2H 2024 to HK$4.8b and HK$0.12 in 2H 2025, against a multi year backdrop of average annual earnings decline of 3.2%. Taken...

If you are wondering whether Xiaomi's current share price gives you good value or not, it helps to separate the story from the numbers and look at what the valuation data is actually saying. The stock last closed at HK$33.30, with returns of 3.4% over the past week, a 6.4% decline over the last month, a 17.3% decline year to date, a 37.0% decline over 1 year, and a 205.5% gain over 3 years, alongside a 27.1% gain over 5 years. Recent coverage has focused on Xiaomi's position as a major...